NASDAQ$SERA
Sera Prognostics Inc-A · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022.
Sera Prognostics reported first quarter 2022 revenue of $38,000, compared to $13,000 for the same period in 2021. The net loss for the quarter was $12.2 million, compared to $6.4 million for the same quarter a year ago. As of March 31, 2022, the Company had cash and cash equivalents of approximately $64.1 million.
- Simplified and streamlined the PreTRM® test ordering process, resulting in increased numbers of orders and ordering physicians.
- Added Dr. Jane F. Barlow to the Board, bringing expertise in bringing novel products and services to the market.
- Engaged in active dialogue with government officials and organizations to reduce healthcare disparities among underserved communities by utilizing our PreTRM® Test.
- Continued pipeline progress including final validation of the first mid-pregnancy proteomic prognostic biomarker for preeclampsia by mid-year 2022.
Headline financials
Revenue & EPS history
Sera Prognostics · Revenue · Quarterly
$38K
Forward guidance
Sera Prognostics is focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients.
Tailwinds
- Increased numbers of orders and ordering physicians are continuing into the current quarter.
- The preeclampsia test is expected to be validated around mid-year 2022.
- Growing recognition of the benefit of PreTRM among and increased adoption with payors, care providers and patients.
- Additional clinical utility and health economic data the Company expects to share later this month.
- The PRIME study is on track for interim readout in 2023.
Headwinds
- Net losses and potential need to raise more capital.
- Revenues from the PreTRM test representing substantially all Company revenues to date.
- The need for broad scientific and market acceptance of the PreTRM test.
- Potential third-party payer coverage and reimbursement.
- Changes in FDA regulation of laboratory-developed tests.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-1.9%
Avg return
Earnings day
-3.5%
Avg return
5 days after
-3.3%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+14.3%
Q3 2022
Best reaction
-11.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -8.0% | +18.1% | |
| Q4 2025 | -7.7% | +6.3% | +20.4% | |
| Q3 2025 | +1.7% | +8.5% | +19.0% | |
| Q1 2025 | -11.7% | -2.1% | -35.4% | |
| Q4 2024 | -5.1% | -2.2% | -17.9% | |
| Q3 2024 | -0.3% | -2.7% | -3.9% | |
| Q2 2024 | +0.0% | -1.2% | -2.2% | |
| Q1 2024 | +3.3% | -4.0% | -13.6% | |
| Q4 2023 | +3.4% | +1.1% | +7.7% | |
| Q3 2023 | -3.2% | -6.4% | +130.9% | |
| Q2 2023 | +0.8% | -10.1% | -39.9% | |
| Q1 2023 | -0.8% | -2.8% | -13.0% | |
| Q4 2022 | -10.0% | -9.5% | -22.3% | |
| Q3 2022 | +14.3% | +11.1% | -4.0% | |
| Q2 2022 | -4.1% | -6.3% | -27.3% | |
| Q1 2022 | -7.6% | -17.1% | -32.7% | |
| Q4 2021 | +3.6% | +0.3% | -39.3% | |
| Q3 2021 | +0.3% | -0.8% | -8.2% | |
| Q3 2020 | +0.3% | -0.8% | -8.2% | |
| Q2 2021 | -4.8% | -9.9% | +0.0% | |
| Q1 2021 | -4.8% | -9.9% | +0.0% | |
| Q4 2020 | -4.8% | -9.9% | +0.0% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro